MiniMed Group Inc (NASDAQ:MMED) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of MiniMed Group Inc (NASDAQ:MMED) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $21.6667.

Several equities research analysts recently issued reports on the stock. Evercore assumed coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued an “outperform” rating and a $20.00 target price on the stock. William Blair assumed coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued an “outperform” rating on the stock. Citigroup assumed coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $23.00 target price on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $20.00 target price on the stock. Finally, BTIG Research began coverage on MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $25.00 target price on the stock.

MiniMed Group Stock Up 0.1%

NASDAQ MMED opened at $10.89 on Wednesday. MiniMed Group has a one year low of $10.65 and a one year high of $20.48. The stock has a 50-day simple moving average of $14.08.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.